Obesity Surgery

, Volume 28, Issue 4, pp 982–989 | Cite as

Diabetes Outcomes More than a Decade Following Sustained Weight Loss After Laparoscopic Adjustable Gastric Band Surgery

  • John M. Wentworth
  • Chloe Cheng
  • Cheryl Laurie
  • Stewart Skinner
  • Paul R. Burton
  • Wendy A. Brown
  • Paul E. O’Brien
Original Contributions



Long-term outcome data are needed to define the role of bariatric surgery in type 2 diabetes (T2D). To address this, we collated diabetes outcomes more than a decade after laparoscopic adjustable gastric band (LAGB) surgery.


Clinical and biochemical measures from 113 obese T2D patients who underwent LAGB surgery in 2003 and 2004 were analyzed. Diabetes remission was defined as HbA1c < 6.2% (44 mmol/mol) and fasting glucose < 7.0 mmol/L.


Seventy-nine patients had weight data at 10 years and attained a median [Q1, Q3] weight loss of 16 [10, 21] percent. Sixty patients attended a follow-up assessment. Their baseline HbA1c of 7.8 [7.1, 9.3] percentage units (62 [54, 78] mmol/mol) had decreased to 6.6 [6.1, 8.4] (49 [43, 68] mmol/mol) despite no significant change in glucose-lowering therapy. Eleven patients (18%) were in diabetes remission and another 18 had HbA1c ≤ 6.5%. Significant improvements in physical measures of quality of life, blood pressure, and lipid profile were also observed but there was no change in the proportion of patients with albuminuria and a significant decline in estimated glomerular filtration rate. Twelve patients in the follow-up cohort (20%) required anti-reflux medication after surgery and 26 (43%) underwent gastric band revision surgery.


Weight loss for over 10 years after LAGB surgery delivers clinically meaningful improvements in HbA1c, blood pressure, lipids, and quality of life at the cost of a high rate of revision surgery and increased use of anti-reflux medication. These findings support the use of bariatric surgery as a long-term treatment for weight loss and wellbeing in patients with T2D.

Study Registration

Registered with the Australian Clinical trials registry as ACTRN12615000089538.


Bariatric surgery Type 2 diabetes Obesity Long-term Outcomes Quality of life Laparoscopic adjustable gastric band 



We are grateful to our patients for their assistance. This work was supported by a competitive Diabetes Research Grant from Novo Nordisk, through Victorian State Government Operational Infrastructure Support and NHMRC Research Institute Infrastructure Support Scheme.

Author Contributions

JMW conceived the study. PEO, PRB, WAB, and SS provided surgical care and, with JMW, CL and CC collated the data. JMW and CC analyzed the data. JMW drafted the manuscript and all authors reviewed and edited it. JMW is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Compliance with Ethical Standards

Conflict of Interest

Prof O’Brien and Prof Brown report being affiliated with the Centre for Obesity Research and Education. The Centre has received funding for research purposes from Allergan and Apollo Endosurgery, the manufacturers of the Lap-Band™. The grant was not tied to any specific research project, and neither Allergan nor Apollo Endosurgery has no control of the protocol, analysis and reporting of any studies. CORE also receives a grant from Applied Medical towards educational programs. Prof Brown reports financial support for a bariatric surgery registry from the Commonwealth of Australia, Apollo Endosurgery, Covidien, Johnson and Johnson, Gore and Applied Medical. Since initial submission of this paper, she has also received a speaker’s honorarium from Merck Sharpe and Dohme and a speaker’s honorarium and fees from participation in a scientific advisory board from Novo Nordisk. The Bariatric Registry and the honorariums are outside of the submitted work. Prof O’Brien has written a patient information book entitled “The Lap-Band Solution: A partnership for weight loss” which is given to patients without charge, but some are sold to surgeons and others, for which he receives a royalty. Dr. Burton reports personal fees from Covidien, outside the submitted work. No other author has a conflict of interest to declare.

Statement of Informed Consent

Informed consent was obtained from all individual participants who comprised the ‘Included Group’ in the study.

Statement of Human Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Supplementary material

11695_2017_2944_MOESM1_ESM.docx (38 kb)
ESM 1 (DOCX 38.3 kb)
11695_2017_2944_MOESM2_ESM.docx (51 kb)
ESM 2 (DOCX 50.6 kb)


  1. 1.
    American Diabetes A. 7. Obesity management for the treatment of type 2 diabetes. Diabetes Care. 2017;40(Suppl 1):S57–63.CrossRefGoogle Scholar
  2. 2.
    Look ARG, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.CrossRefGoogle Scholar
  3. 3.
    Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012;366(13):1209–17.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Wentworth JM, Burton P, Laurie C, et al. Five-year outcomes of a randomized trial of gastric band surgery in overweight but not obese people with type 2 diabetes. Diabetes Care. 2017;40(4):e44–e5.CrossRefPubMedGoogle Scholar
  5. 5.
    Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641–51.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964–73.CrossRefPubMedGoogle Scholar
  7. 7.
    Sjoholm K, Sjostrom E, Carlsson LM, et al. Weight change-adjusted effects of gastric bypass surgery on glucose metabolism: 2- and 10-year results from the Swedish Obese Subjects (SOS) study. Diabetes Care. 2016;39(4):625–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Gummesson A, Nyman E, Knutsson M, et al. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(9):1295–1305.Google Scholar
  9. 9.
    Puzziferri N, Roshek 3rd TB, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA. 2014;312(9):934–42.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Arterburn DE, Fisher DP. The current state of the evidence for bariatric surgery. JAMA. 2014;312(9):898–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Khorgami Z, Shoar S, Andalib A, et al. Trends in utilization of bariatric surgery, 2010–2014: sleeve gastrectomy dominates. Surg Obes Relat Dis. 2017;13(5):774–8.Google Scholar
  12. 12.
    Flum DR, Belle SH, Longitudinal Assessment of Bariatric Surgery, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361(5):445–54.CrossRefPubMedGoogle Scholar
  13. 13.
    O'Brien PE, MacDonald L, Anderson M, et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg. 2013;257(1):87–94.CrossRefPubMedGoogle Scholar
  14. 14.
    Wentworth JM, Playfair J, Laurie C, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2(7):545–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21(12):2191–2.CrossRefPubMedGoogle Scholar
  16. 16.
    Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316–23.CrossRefPubMedGoogle Scholar
  17. 17.
    Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133–5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Himpens J, Cadiere GB, Bazi M, et al. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg. 2011;146(7):802–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.CrossRefPubMedGoogle Scholar
  20. 20.
    Sjostrom L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304.CrossRefPubMedGoogle Scholar
  21. 21.
    Ooi GJ, Doyle L, Tie T, et al. Weight loss after laparoscopic adjustable gastric band and resolution of the metabolic syndrome and its components. Int J Obes. 2017;41(6):902–8.CrossRefGoogle Scholar
  22. 22.
    Keating C, Neovius M, Sjoholm K, et al. Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol. 2015;3(11):855–65.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis. 2010;6(3):249–53.CrossRefPubMedGoogle Scholar
  24. 24.
    Benetti A, Del Puppo M, Crosignani A, et al. Cholesterol metabolism after bariatric surgery in grade 3 obesity: differences between malabsorptive and restrictive procedures. Diabetes Care. 2013;36(6):1443–7.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Naik RD, Choksi YA, Vaezi MF. Consequences of bariatric surgery on oesophageal function in health and disease. Nat Rev Gastroenterol Hepatol. 2016;13(2):111–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Chen RY, Burton PR, Ooi GJ, et al. The physiology and pathophysiology of gastroesophageal reflux in patients with laparoscopic adjustable gastric band. Obes Surg. 2017.
  27. 27.
    Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Rubin RR, Wadden TA, Bahnson JL, et al. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care. 2014;37(6):1544–53.CrossRefPubMedGoogle Scholar
  29. 29.
    Wentworth JM, Dalziel KM, O'Brien PE, et al. Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S. J Diabetes Complicat. 2017;31(7):1139–44.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Hoerger TJ, Zhang P, Segel JE, et al. Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care. 2010;33(9):1933–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Monash University Centre for Obesity Research and EducationMelbourneAustralia
  2. 2.Walter and Eliza Hall InstituteParkvilleAustralia
  3. 3.University of Melbourne Department of MedicineParkvilleAustralia

Personalised recommendations